217 related articles for article (PubMed ID: 38364100)
1. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients.
Marques AD; Graham-Wooten J; Fitzgerald AS; Sobel Leonard A; Cook EJ; Everett JK; Rodino KG; Moncla LH; Kelly BJ; Collman RG; Bushman FD
mBio; 2024 Mar; 15(3):e0011024. PubMed ID: 38364100
[TBL] [Abstract][Full Text] [Related]
2. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.
Andrés C; González-Sánchez A; Jiménez M; Márquez-Algaba E; Piñana M; Fernández-Naval C; Esperalba J; Saubi N; Quer J; Rando-Segura A; Miarons M; Codina MG; Ruiz-Camps I; Pumarola T; Abrisqueta P; Antón A
Clin Microbiol Infect; 2023 Feb; 29(2):240-246. PubMed ID: 36067943
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
6. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.
Leducq V; Zafilaza K; Fauchois A; Ghidaoui E; Sayon S; Dorival C; Meledje ML; Lusivika-Nzinga C; Yordanov Y; Martin-Blondel G; Carrat F; Marcelin AG; Soulie C
J Infect Dis; 2024 May; 229(5):1341-1351. PubMed ID: 37996072
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Genome Variations in Viral Shedding of an Immunocompromised Patient with Non-Hodgkin's Lymphoma.
Villaseñor-Echavarri R; Gomez-Romero L; Martin-Onraet A; Herrera LA; Escobar-Arrazola MA; Ramirez-Vega OA; Barrientos-Flores C; Mendoza-Vargas A; Hidalgo-Miranda A; Vilar-Compte D; Cedro-Tanda A
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851588
[TBL] [Abstract][Full Text] [Related]
9. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.
Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L
Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471
[TBL] [Abstract][Full Text] [Related]
10. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment.
Ahmadi AS; Zadheidar S; Sadeghi K; Nejati A; Salimi V; Hajiabdolbaghi M; Mokhtari-Azad T; Yavarian J
J Med Virol; 2023 Jun; 95(6):e28877. PubMed ID: 37341553
[TBL] [Abstract][Full Text] [Related]
12. Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.
Nussenblatt V; Roder AE; Das S; de Wit E; Youn JH; Banakis S; Mushegian A; Mederos C; Wang W; Chung M; Pérez-Pérez L; Palmore T; Brudno JN; Kochenderfer JN; Ghedin E
J Infect Dis; 2022 Apr; 225(7):1118-1123. PubMed ID: 34940844
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.
Hirotsu Y; Kobayashi H; Kakizaki Y; Saito A; Tsutsui T; Kawaguchi M; Shimamura S; Hata K; Hanawa S; Toyama J; Miyashita Y; Omata M
Med; 2023 Nov; 4(11):813-824.e4. PubMed ID: 37683636
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient.
Quaranta EG; Fusaro A; Giussani E; D'Amico V; Varotto M; Pagliari M; Giordani MT; Zoppelletto M; Merola F; Antico A; Stefanelli P; Terregino C; Monne I
Int J Infect Dis; 2022 Sep; 122():444-448. PubMed ID: 35724829
[TBL] [Abstract][Full Text] [Related]
15. Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts.
Ko KKK; Yingtaweesittikul H; Tan TT; Wijaya L; Cao DY; Goh SS; Abdul Rahman NB; Chan KXL; Tay HM; Sim JHC; Chan KS; Oon LLE; Nagarajan N; Suphavilai C
Microbiol Spectr; 2022 Jun; 10(3):e0079122. PubMed ID: 35543562
[TBL] [Abstract][Full Text] [Related]
16. Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Huygens S; Oude Munnink B; Gharbharan A; Koopmans M; Rijnders B
Clin Infect Dis; 2023 Feb; 76(3):e507-e509. PubMed ID: 35867699
[TBL] [Abstract][Full Text] [Related]
17. Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient.
Alisoltani A; Simons LM; Agnes MFR; Heald-Sargent TA; Muller WJ; Kociolek LK; Hultquist JF; Lorenzo-Redondo R; Ozer EA
Virol J; 2023 Oct; 20(1):246. PubMed ID: 37891657
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
Truffot A; Andréani J; Le Maréchal M; Caporossi A; Epaulard O; Germi R; Poignard P; Larrat S
Emerg Infect Dis; 2021 Oct; 27(10):2725-2728. PubMed ID: 34352197
[TBL] [Abstract][Full Text] [Related]
19. Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
Guilbaud R; Franco Yusti AM; Leducq V; Zafilaza K; Bridier-Nahmias A; Todesco E; Soulie C; Fauchois A; Le Hingrat Q; Kramer L; Goulenok T; Salpin M; Daugas E; Dorent R; Ottaviani S; Zalcman G; Ghosn J; Choquet S; Cacoub P; Amoura Z; Barroux B; Pourcher V; Spano JP; Louet M; Marcelin AG; Calvez V; Charpentier C; Descamps D; Marot S; Ferré VM; Coppée R
J Infect Dis; 2024 Apr; 229(4):1041-1049. PubMed ID: 37956413
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 shedding dynamics and transmission in immunosuppressed patients.
Lee JS; Yun KW; Jeong H; Kim B; Kim MJ; Park JH; Shin HS; Oh HS; Sung H; Song MG; Cho SI; Kim SY; Kang CK; Choe PG; Park WB; Kim NJ; Oh MD; Choi EH; Park S; Kim TS; Lee JH; Sung H; Park SS; Seong MW
Virulence; 2022 Dec; 13(1):1242-1251. PubMed ID: 35891618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
